Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: A multicentre randomised study

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 12, 2003, Pages 1471-1480

  Campieri, M ^a   Adamo, S ^b   Valpiani, D ^c   D'Arienzo, A ^d   D'Albasio, G ^e   Pitzalis, M ⁱ   Cesari, P ^f   Casetti, T ^g   Castiglione, G N ^h   Rizzello, F ^a   Manguso, F ^d   Varoli, G ^h   Gionchetti, P ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Bussolengo Hospital   (Italy)

^c MORGAGNI PIERANTONI HOSPITAL   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f S Orsola Hospital   (Italy)

^g SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^h CHIESI FARMACEUTICI S P A   (Italy)

ⁱ Osp Policlinico S Orsola Malpighi ^*

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; HYDROCORTISONE; STEROID;

ADRENAL FUNCTION; ADULT; ARTICLE; BLOOD CHEMISTRY; CLINICAL TRIAL; COLONOSCOPE; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MENORRHAGIA; MULTICENTER STUDY; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; BECLOMETHASONE; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0037560155     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01609.x     Document Type: Article

References (34)

1. Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000; 95: 1628-36.
2. Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996; 31: 260-6.
3. Green JR. Lobo AJ. Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998; 114: 15-22.
4. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989; 298: 82-6.
5. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955; 2: 1041-8.
6. Geier DL, Miner PB Jr. New therapeutic agents in the treatment of inflammatory bowel disease. Am J Med 1992; 93: 199-208.
7. Harris DM. Some properties of beclomethasone dipropionate and related steroids in man. Postgrad Med J 1975; 51: 20-5.
8. Ardizzone S, Bianchi Porto GB. A practical guide to the management of distal ulcerative colitis. Drugs 1998; 55: 519-42.
9. Campieri M, Cottone M, Miglio F, et al. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. Aliment Pharmacol Ther 1998; 12: 361-6.
10. Halpern Z, Sold O, Baratz M, Konikoff F, Halak A, Gilat T. A controlled trial of beclomethasone versus betamethasone enemas in distal ulcerative colitis. J Clin Gastroenterol 1991; 13: 38-41.
11. Bansky G, Buhler H, Stamm B, Hacki WH, Buchmann P, Muller J. Treatment of distal ulcerative colitis with beclomethasone enemas: high therapeutic efficacy without endocrine side effects. A prospective, randomized, double-blind trial. Dis Colon Rectum 1987; 30: 288-92,
12. Tytgat GNJ, Van Der Heide H, Van Den Brandt-Gradel V, Endert E, Wiersinga W. Comparison of beclomethasone dipropionate (BDP) and prednisolone 21-phosphate (PP) enemas in distal ulcerative colitis. A double blind study. Gastroenterology 1985; 88: 1620.
13. Van der Heide H, Van den Brandt-Gradel V, Tytgat GN, et al. Comparison of bedomethasone dipropionate and prednisolone 21-phosphate enemas in the treatment of ulcerative proctitis. J Clin Gastroenterol 1988; 10: 169-72.
14. Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN. Beclomethasone dipropionate (3 mg) versus 5-aminosalicyllc acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996; 8: 549-53.
15. Campieri M, Gionchetti P, Belluzzi A, et al. Topical treatment of ulcerative colitis using enemas containing 5-aminosalicylic acid and beclomethasone dipropionate. Can J Gastroenterol 1990; 4: 481-3.
16. Steed KP, Hooper G, Ventura P, Musa R, Wilding IR. The in vivo behaviour of a colonic delivery system: a pilot study in man. Int J Pharmaceutics 1994; 112: 199-206.
17. Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001; 48: 571-7.
18. Sutherland LR, Martin F, Greet S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894-8.
19. Rizzello F, Gionchetti P, D'Arienzo A, et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002; 16: 1109-16.
20. Baron JH, Cornell AH, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br. Med J 1964; 1: 89-96.
21. Truelove SC, Richard WCD. Biopsy studies in ulcerative colitis. Br Med J 1956; 1: 1315-8.
22. Sandborn WJ, Tremaine WJ, Schroeder KW, Steiner BL, Batts KP, Lawson GM. Cyclosporine enemas for treatment-resistant. mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol 1993; 88: 640-5.
23. Braunwald E, Fauci AS, Isselbacher KJ, et al., eds. Harrison's Principles of Internal Medicine. Fifteenth Edition. New York: McGraw-Hill, 2001: A-6.
24. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology. Practice Parameters Committee. Am J Gastroenterol 1997; 92: 204-11.
25. British Society of Gastroenterology. Guidelines in Gastroenterology 4. Inflammatory Bowel Disease. London: BSG, 1996.
26. Truelove SC. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium: a report on a controlled therapeutic trial. Br Med J 1958; 2: 1072-7.
27. Hanauer SB, Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf 1991; 6: 192-219.
28. Kumana CR, Seaton T, Meghji M, Castelli M, Benson R, Sivakumaran T. Beclomethasone dipropionate enemas for treating inflammatory bowel disease without producing Cushing's syndrome or hypothalamic pituitary adrenal suppression. Lancet 1982; 1: 579-83.
29. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997; 40: 775-81.
30. Brogden RN, Heel RC, Speight TM, Avery GS, Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis. Drugs 1984; 28: 99-126.
31. Rizzello F, Gionchetti P, Galeazzi R, et al. Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study. Adv Ther 2001; 18: 261-71.
32. D'Arienzo A, Manguso F, Castiglione GN, et al. Beclomethasone dipropionate (3 mg) enemas combined with oral 5-ASA (2.4 g) in the treatment of ulcerative colitis not responsive to oral 5-ASA alone. Ital J Gastroenterol Hepatol 1998; 30: 254-7.
33. Riley SA. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut 1998; 42: 761-3.
34. Rao SS, Read NW, Brown C, Bruce C, Holdsworth CD. Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology 1987; 93: 934-40.